

# Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912



1<sup>st</sup> February, 2020

To,  
The Listing Department  
**BSE Limited**  
PhirozeJeejeebhoy Towers,  
Dalal Street  
Mumbai – 400 001

Listing Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, BandraKurla Complex  
Bandra (East)  
Mumbai – 400 051

Scrip Code : 524518

Name of Scrip : KREBSBIO

Dear Sir / Madam,

## **Sub : Outcome of Board Meeting**

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ["SEBI LODR Regulations"], we wish to inform the following outcome of the meeting of the Board of Directors held today, i.e. 1<sup>st</sup> February, 2020 :

- (a) The unaudited financial results for the quarter ended 31<sup>st</sup> December, 2019 along with the Limited Review Report thereon (Enclosed herewith).


Kindly note that the meeting was commenced at 11.30 AM and concluded at 01.30PM

You are requested to take note of the above.

Thanking you,

Yours faithfully,  
For Krebs Biochemicals & Industries Limited

  
Taruni Banda  
Company Secretary



CIN:L24110AP1991PLC103912

**Corporate Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No: 8, Banjara Hills, Hyderabad - 500 034**

## (Rs. In lacs)

1	The above results have been reviewed by the Audit Committee at its meeting held on 01st February 2020 and approved by the Board of Directors of the Company at its meeting held on 01st February 2020 The results are subjected to limited review by statutory auditors.
2	The Company is operating in one segment only hence no segment results have been disclosed.
3	The Company has adopted Ind AS-116, effective annual reporting period beginning April 1, 2019 and applied the standard to its leases. However, there is no impact on the financials of the Company.
4	The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015.
5	The figures for the corresponding previous period have been regrouped / reclassified wherever necessary, to make them comparable.

Date: 01.02.2020

**Managing Director**

DIN : 01616152





**Limited Review Report**

**Review Report to  
The Board of Directors,  
KREBS BIOCHEMICALS & INDUSTRIES LIMITED**

- a) We have reviewed the accompanying statement of unaudited standalone financial results of **M/s. KREBS BIOCHEMICALS & INDUSTRIES LIMITED** ("the company") for the quarter ended **31<sup>st</sup> December, 2019** and the year to date from 1<sup>st</sup> April 2019 to 31<sup>st</sup> December 2019 (the "Statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with SEBI circular No CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July 2016.
- b) The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and SEBI circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express a conclusion on the statement based on our review.
- c) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- d) Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other recognized accounting practices and policies has disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Bhavani & Co.  
Chartered Accountants  
Firm Registration No: 0121395

CA S Kavitha Padmini  
Partner

Membership no: 229966

UDIN : 20229966AAAAH7915

Place : Hyderabad  
Date : 01/02/2020

